Q-omics provides the consensus-scored LRRC4 profile across patient tissues and cancer cell-line models. LRRC4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC4 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, LRRC4 RNA expression shows 19,293 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRP as cancer lineages where LRRC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC4 survival associations across molecular data types. LRRC4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC4 RNA expression–survival associations across cancer types. High LRRC4 expression shows unfavorable associations in UVM and BLCA, but favorable associations in UCEC, KIRC, LGG and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC4 RNA expression.
This table summarizes LRRC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC4 shows lower tumor expression in KIRP, LUAD, KIRC, STAD and LIHC and higher tumor expression in THCA. The KIRP box plot shows higher LRRC4 RNA expression in normal versus tumor tissue (log2 FC = −2.009, t-test p < 0.001).
This table shows molecular features associated with LRRC4 in patient tissues and cancer cell lines. In patient samples, LRRC4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
